Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-25-245268
Filing Date
2025-10-21
Accepted
2025-10-21 16:57:38
Documents
2
Period of Report
2025-10-20

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2169
2 EX-24 achv-ex24.htm EX-24 14147
  Complete submission text file 0001193125-25-245268.txt   17999
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O ACHIEVE LIFE SCIENCES, INC. 22722 29TH DR. SE, SUITE 100 BOTHELL WA 98021
Business Address
Atkisson Erik (Reporting) CIK: 0001885915 (see all company filings)

Type: 3 | Act: 34 | File No.: 033-80623 | Film No.: 251407760